I wouldn't necessarily say that. No way are they worth billions before the merger but definitely worth more than the ~$30 million market cap we were trading at. I would put a valuation of $TPIV in it's current state, not taking into account the merger, of ~$300 million or about $15 per share fully diluted tops. I wouldn't go any higher than that without more data. I'm sure some people had lofty expectations but in the end the main point, for me anyways, was it's definitely worth more than $30 million. Either way it's a moot point at this stage because the combined company will be worth way more than $30 million or even $300 million, IMO. While Marker's therapies are worth a lot more than Tapimmune's that doesn't mean people were overestimating the value of $TPIV.
News 
Market Data 
Discover 
